Iyer, Abishek and Fenning, Andrew and Lim, Junxian and Le, Giang T. and Reid, Robert C. and Halili, Maria A. and Fairlie, David P. and Brown, Lindsay (2010) Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats: research paper. British Journal of Pharmacology, 159 (7). pp. 1408-1417. ISSN 0007-1188
Text (Accepted Version)
Background and purpose: Histone deacetylases (HDACs) silence genes by deacetylating lysine residues in histones and other proteins. HDAC inhibitors represent a new class of compounds with anti-inflammatory activity. This study investigated whether treatment with a broad spectrum HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), would prevent cardiac fibrosis, part of the cardiovascular remodelling in deoxycorticosterone acetate (DOCA)-salt rats.
Experimental approach: Control and DOCA-salt rats were treated with SAHA (25 mg·kg−1·day−1 s.c.) for 32 days. Changes in cardiovascular structure and function were assessed by blood pressure in vivo and in Langendorff perfused hearts, ventricular papillary muscle and in aortic rings in vitro. Left ventricular collagen deposition was assessed by histology.
Key results: Administration of SAHA to DOCA-salt rats attenuated the following parameters: the increased concentration of over 20 pro-inflammatory cytokines in plasma, increased inflammatory cell infiltration and interstitial collagen deposition, increased passive diastolic stiffness in perfused hearts, prolongation of action potential duration at 20% and 90% of repolarization in papillary muscle, development of left ventricular hypertrophy, systolic hypertension and changes in vascular dysfunction.
Conclusions and implications: The HDAC inhibitor, SAHA, attenuated the cardiovascular remodelling associated with DOCA-salt hypertensive rats and improved cardiovascular structure and function, especially fibrosis, in the heart and blood vessels, possibly by suppressing inflammation. Control of cardiac histone or non-histone protein acetylation is a potential therapeutic approach to preventing cardiac remodelling, especially cardiac fibrosis.
Statistics for this ePrint Item
|Item Type:||Article (Commonwealth Reporting Category C)|
|Publisher:||John Wiley & Sons Ltd.|
|Item Status:||Live Archive|
|Additional Information (displayed to public):||Accepted version deposited in accordance with the copyright policy of the publisher.|
|Depositing User:||Professor Lindsay Brown|
|Faculty / Department / School:||Historic - Faculty of Sciences - Department of Biological and Physical Sciences|
|Date Deposited:||10 Oct 2010 06:19|
|Last Modified:||25 Aug 2014 02:55|
|Uncontrolled Keywords:||histone acetyltransferase; histone deacetylase inhibitor; cardiac remodelling; hypertrophy; fibrosis; hypertension|
|Fields of Research (FoR):||11 Medical and Health Sciences > 1102 Cardiovascular Medicine and Haematology > 110299 Cardiovascular Medicine and Haematology not elsewhere classified
11 Medical and Health Sciences > 1115 Pharmacology and Pharmaceutical Sciences > 111501 Basic Pharmacology
11 Medical and Health Sciences > 1101 Medical Biochemistry and Metabolomics > 110106 Medical Biochemistry: Proteins and Peptides (incl. Medical Proteomics)
|Socio-Economic Objective (SEO):||C Society > 92 Health > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases|
|Identification Number or DOI:||doi: 10.1111/j.1476-5381.2010.00637.x|
Actions (login required)
|Archive Repository Staff Only|